Navigation Links
Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
Date:3/2/2009

SAN DIEGO, March 2 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX) today announced that Patrick Mahaffy has been appointed to the Company's Board of Directors to fill an existing vacancy on the board.

Mr. Mahaffy brings significant biotechnology and pharmaceutical executive management experience. He was the founder of Pharmion Corporation and served as its President and CEO from its inception through its acquisition eight years later. Under Mr. Mahaffy's leadership, Pharmion successfully acquired, developed and gained approval for several oncology products in the U.S. and Europe and achieved significant revenues and sustained growth from those products until its acquisition by Celgene Corporation for $2.9 billion in March 2008. Mr. Mahaffy is presently creating a new company dedicated to acquiring and developing oncology drug products.

"Patrick has a proven track record in successfully managing all facets of drug development and commercialization, and his experience will be incredibly valuable as we complete the Phase 3 program for Contrave, our lead obesity product candidate," said Eckard Weber, M.D., Executive Chairman and Interim President and CEO. "In addition, his knowledge and experience in strategic business development will be important as we continue to explore partnership opportunities and execute on broader business strategies."

Prior to co-founding Pharmion, Mr. Mahaffy was President and CEO of NeXagen, Inc. and its successor, NeXstar Pharmaceuticals Inc. from 1992 until 1999. He is credited for developing corporate partnerships with Eli Lilly and Co., Systemix/Sandoz, Schering AG and Becton, Dickinson and Co. He took NeXstar Pharmaceuticals public in 1994 and in 1995 acquired publicly-traded company Vestar. In July 1999, Gilead acquired NeXstar Pharmaceuticals for $800 million. Mr. Mahaffy received a B.A. from Lewis and Clark College and an M.A. from Columbia School of International Affairs.

About Orexigen(R) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Prime Therapeutics Receives TIPPS Certification
4. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
5. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
6. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
7. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
8. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
9. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
10. Prime Therapeutics Announces URAC Accreditation
11. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... Online HR/benefits platforms offer a ... the game for traditional brokers and health plans. “ The Rapid Emergence of Online ... from Atlantic Information Services, Inc. (AIS), will offer an accurate picture of online benefits ...
(Date:5/6/2016)... ... ... From the Speaker Podium to the Exhibit Floor at Booth#514, Worldwide Leading Contact Center ... at SpeechTek 2016 Event, taking place May 23-25 at the Omni Shoreham in Washington ... “5 Customer Engagement Strategies to improve Customer Satisfaction in your Contact Center” on May ...
(Date:5/6/2016)... NY (PRWEB) , ... May 06, 2016 , ... The ... & Resort on the north end of the island close to the town famous ... 17th- August 10th 2016. , “We continue to have an amazing experience in ...
(Date:5/6/2016)... ... May 06, 2016 , ... Multiple award winning plumbing company ... over 35 years. Maintaining core values of exceptional customer service, quality work at reasonable ... a leading name in San Diego plumbing, and other services including heating & air ...
(Date:5/6/2016)... ... 2016 , ... Few events in healthcare changed the landscape ... cost despite its potential to wipe out a silent killer, hepatitis C virus. ... called direct-acting antivirals (DAAs)—have created fallout in the courts and state governments. Advocates ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... Research and Markets has ... Ischemic Stroke Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Ischemic Stroke epidemiology, Acute Ischemic ...
(Date:5/4/2016)... , May 4, 2016 ... addition of the  "Global Actinic Keratosis Market ... to their offering.       (Logo: ... Keratosis Market and Competitive Landscape Highlights 2016, ... products, Actinic Keratosis epidemiology, Actinic Keratosis market ...
(Date:5/3/2016)... PUNE, India , May 4, 2016 /PRNewswire/ ... report spreads across 154 pages, profiling 09 key ... It is a professional and in-depth study on ... providing a basic overview of the industry including ... Insulin Needles market analysis is provided for the ...
Breaking Medicine Technology: